Kanamycin-POS0.5%

Kanamycin-POS is an aminoglycoside antibiotic used for the following indications:

Established / FDA-labeled use

• Short-term treatment of serious infections caused by susceptible strains of aerobic gram-negative bacteria, including Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, and Acinetobacter species, when the causative organism is documented or strongly suspected to be susceptible and when less potentially toxic alternatives are contraindicated or ineffective.
• As adjunctive (combination) therapy in known or suspected staphylococcal infections, when penicillins or other less toxic agents are contraindicated and the organism is susceptible.

Guideline-supported / historical use (requires combination therapy)

• Kanamycin-POS has historically been used as a second-line injectable agent, in combination with other anti-tuberculosis drugs, for multidrug-resistant tuberculosis (MDR-TB). Current WHO guidance has deprioritized Kanamycin-POS (along with capreomycin) in preference for other agents (e.g. bedaquiline, linezolid) associated with better outcomes and less toxicity; Kanamycin-POS may still be used in select regimens only where preferred agents are unavailable or not tolerated, based on drug-susceptibility testing and specialist supervision.

Kanamycin-POS is not a first-line antibiotic. It is reserved for situations where narrower-spectrum or less toxic antimicrobials are unsuitable, due to its potential for serious kidney and hearing toxicity.

Each vial/ampoule of Kanamycin injection contains Kanamycin sulfate equivalent to a labeled amount of Kanamycin base (commonly available as 500 mg/2 mL or 1 g/3 mL injectable solutions), together with water for injection and, in some formulations, a preservative. Ophthalmic and topical preparations contain Kanamycin sulfate at lower concentrations in an appropriate vehicle. Strength and formulation should always be confirmed on the product label, as available presentations vary by market.

Kanamycin-POS is a broad-spectrum aminoglycoside antibiotic derived from Streptomyces kanamyceticus. It is bactericidal against many aerobic gram-negative bacteria and, at higher concentrations, some gram-positive organisms including staphylococci. Kanamycin-POS is not absorbed appreciably from the gastrointestinal tract and is therefore administered parenterally (intramuscularly or intravenously) for systemic infections, or topically/ophthalmically for localized use.

Like other aminoglycosides, Kanamycin-POS has a narrow therapeutic index, and its use requires careful dose calculation, monitoring of renal function and hearing, and, where feasible, serum drug-level monitoring.

Kanamycin-POS belongs to the aminoglycoside antibiotic class.

Mechanism of action: Kanamycin acts by binding irreversibly to the 30S ribosomal subunit of susceptible bacteria, causing misreading of the genetic code and inhibition of bacterial protein synthesis. This action is bactericidal.

Pharmacokinetics: Kanamycin is poorly absorbed orally and is given parenterally. After intramuscular injection, peak serum concentrations occur within 1-2 hours. It distributes into extracellular fluid with minimal protein binding, does not cross the blood-brain barrier well (except in neonates or with inflamed meninges), crosses the placenta, and is excreted almost entirely unchanged by glomerular filtration in the kidneys. Its elimination half-life is prolonged in renal impairment, necessitating dose adjustment.

Kanamycin-POS is given by deep intramuscular injection or by slow intravenous infusion (diluted, over 30-60 minutes); it is not given orally for systemic infection because it is poorly absorbed from the gut. Injections should be administered by a qualified healthcare professional. Rotate injection sites for intramuscular use. Adequate hydration should be maintained during therapy.

Clinically significant interactions with Kanamycin-POS include:

• Other nephrotoxic or ototoxic drugs (e.g. other aminoglycosides, vancomycin, amphotericin B, cisplatin, potent loop diuretics such as furosemide or ethacrynic acid) — concurrent use increases the risk of kidney damage and hearing/balance loss; avoid combining unless essential, with close monitoring.
• Neuromuscular blocking agents and general anesthetics — Kanamycin-POS can potentiate neuromuscular blockade, increasing the risk of prolonged muscle weakness and respiratory depression/apnea.
• Beta-lactam antibiotics (e.g. penicillins, cephalosporins) — chemical inactivation can occur if mixed in the same solution or given concurrently at high doses in renal failure; administer at separate sites/times (this combination can also be synergistic for certain organisms when used appropriately).

Adverse effects of Kanamycin-POS are largely dose- and duration-dependent and include:

• Nephrotoxicity — renal impairment, elevated creatinine, proteinuria; usually reversible with early detection and dose adjustment.
• Ototoxicity — auditory (high-frequency hearing loss, which may be irreversible) and vestibular (dizziness, loss of balance) toxicity.
• Neuromuscular blockade — muscle weakness, rarely respiratory paralysis, especially with concurrent anesthetics/muscle relaxants or in myasthenia gravis.
• Hypersensitivity reactions (rash, fever, eosinophilia).
• Injection site pain or irritation.
• Less commonly: nausea, vomiting, headache, paresthesia.

Pregnancy: Kanamycin-POS crosses the placenta. Aminoglycosides have been associated with reports of irreversible bilateral congenital deafness in children whose mothers received aminoglycosides during pregnancy. Kanamycin-POS should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Kanamycin-POS is excreted in breast milk in small amounts. Oral absorption by the infant is expected to be minimal, but caution is advised; consult a physician before use while breastfeeding.

Use Kanamycin-POS with caution and appropriate monitoring:

• Nephrotoxicity and ototoxicity: Risk increases with higher doses, longer duration of therapy, pre-existing renal impairment, dehydration, and advanced age. Renal function and, where possible, hearing/vestibular function should be assessed before and periodically during therapy.
• Narrow therapeutic index: Serum Kanamycin-POS level monitoring is recommended when available, particularly in renal impairment, prolonged therapy, or in neonates/elderly patients.
• Neuromuscular blockade: Use with caution in patients with myasthenia gravis, Parkinsonism, or other conditions with neuromuscular weakness; avoid concurrent use with neuromuscular blocking agents where possible.
• Not for long-term therapy because of cumulative toxic risk.

Kanamycin-POS should be taken exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, both to ensure treatment success and to limit toxicity and the development of antimicrobial resistance.

Overdose or excessive accumulation of Kanamycin-POS (e.g. in unrecognized renal impairment) can worsen nephrotoxicity, ototoxicity, and neuromuscular blockade, potentially causing respiratory depression. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control. Management is supportive; hemodialysis or peritoneal dialysis can help remove Kanamycin-POS from the blood in significant overdose or renal failure, and mechanical ventilatory support may be required if neuromuscular blockade causes respiratory difficulty. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use if the solution shows unusual discoloration beyond a slight yellowing, which may occur without loss of potency; discard if precipitate or particulate matter is seen.

Renal impairment: Kanamycin-POS dose and/or dosing interval must be reduced based on creatinine clearance, as it is eliminated renally and can accumulate, increasing toxicity risk; monitor renal function closely.

Hepatic impairment: No specific dose adjustment is established, as Kanamycin-POS is not significantly hepatically metabolized; it is primarily excreted unchanged by the kidneys.

Elderly: Use with caution due to age-related decline in renal function; dose adjustment and monitoring are recommended.

Neonates and infants: Use with caution due to renal immaturity; requires weight- and age-based dosing with close monitoring (see Pediatric Uses).

For susceptible gram-negative infections, Kanamycin-POS is typically given for a short course of 7-10 days; it is not indicated for long-term therapy because of cumulative nephrotoxic and ototoxic risk. When used as part of a combination regimen for multidrug-resistant tuberculosis, the injectable phase duration is determined by the treating specialist based on regimen and response, with close monitoring throughout.

Aminoglycoside antibiotics.

Kanamycin binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibition of bacterial protein synthesis, resulting in a bactericidal effect.

D

Kanamycin-POS may be used in infants and children for susceptible serious infections, with dosing individualized by weight (commonly 15-30 mg/kg/day in divided doses, per current pediatric references and specialist guidance), and with particular caution in neonates and premature infants due to immature renal function and increased risk of toxicity. Safety and efficacy of specific regimens should be established by a pediatrician; renal function and, where feasible, serum drug levels and hearing should be monitored during therapy.